News

Children are particularly sensitive to systemic side effects of topical glaucoma medications for a variety of reasons. Increased caution is necessary when using these agents.

Achieving alignment of strabismus can be difficult in children with syndromic craniosynostosis as the causes are multifactorial.

Recent randomized clinical trials have been advancing the understanding of current treatments for convergence insufficiency. More prospective studies are needed to investigate convergence types and their roles in convergence insufficiency.

Phase II clinical study results indicate monthly lampalizumab therapy may be successful treatment

Baylor College of Medicine (BCM) has named Timothy Stout, MD, PhD, as its new ophthalmology department chairman.

InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.

Sucampo has announced that its development partner, R-Tech Ueno Ltd., has completed the enrollment of a phase III study for its treatment of retinitis pigmentosa (RP).

Prevent Blindness America (PBA) and several of its partners have joined together to launch a new initiative called the “Year of Children’s Vision” (YOCV).

Obamacare’s provision stating vision services for children are essential will help increase the number of young people able to receive check-ups and follow-up care, which are crucial for their well being.

Inclusion of clinically relevant genetic markers improves the accuracy of predicting risk of progression to choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) beyond a prediction based on only phenotypic risk factors, according to a recent cohort study.

Alimera Sciences Inc. has received a complete response letter (CRL) for the new drug application (NDA) for its sustained-release intravitreal implant, Iluvien, from the FDA.

The FDA has cleared the use of corneal and arcuate incisions on Ziemer Ophthalmic Systems’ femtosecond laser platform during cataract surgery.

The final early benefit assessment from the German Federal Joint Committee (G-BA) has concluded that ThromboGenics’ ocriplasmin (Jetrea) demonstrates significant added benefit for vitreomacular traction (VMT) patients with mild and moderate symptoms.

The American Academy of Ophthalmology (AAO) has announced its newly redesigned Ophthalmic News and Education (ONE) Network, an online source of peer-reviewed news and education for ophthalmologists.

The FDA has approved Allegro Ophthalmics’ investigational new drug application to begin phase II clinical studies of ALG-1001, an integrin peptide therapy.

Omeros Corp. has announced that the new drug application (NDA) for its new product, OMS302, has been confirmed for filing by the FDA.

Refractive surgery is a safe method for correcting refractive error, according to a retrospective review of all cases of the surgery performed over a 7-year period at a U.S. military laser refractive surgery center.

In my practice ORA is invaluable, and I can’t imagine performing surgery without it. The technology has evolved greatly since the first-generation system was introduced, and its accuracy amazes me.

The 2013 Ophthalmology Innovation Summit will convene Nov. 14 in New Orleans. Visit www.ophthalmologysummit.com for updates or to register.

The 2013 meeting of the American Academy of Ophthalmology will convene in New Orleans from Nov. 16 to 19. Visit www.aao.org for the latest updates or to register.

The Laser Anterior Ciliary Excision procedure uses laser scleral micro-excisions to alter ocular rigidity to rejuvenate aging sclera.

Cataract surgery performed with intraoperative wavefront aberrometry while implanting a new aspheric hydrophobic acrylic IOL maximizes visual acuity and quality-of-vision results.

Many individuals with diabetic retinopathy do not know that the disease affects vision. Furthermore, Hispanics are more likely to be unaware of the presence of this disease, indicated a nationally representative study.

The chronicity of neovascular age-related macular degeneration and the burden of frequent intravitreal anti-vascular endothelial growth factor injections are driving research to develop long-term delivery therapeutic strategies.

An injectable intraocular sustained release drug delivery system demonstrated favorable safety and efficacy results in a multicenter phase II clinical trial.

Immediately sequential bilateral cataract surgery may be in peril as a procedure because it is penalized to varying degrees by government-imposed reimbursement cuts.